tetrahydrocannabinol + cannabidiol (BOL Pharma)

THC + CBD is a cannabinoid-based sublingual tablet in preclinical development by BOL Pharma, an Israeli medical cannabis company. The drug combines two active cannabinoid ingredients — tetrahydrocannabinol (THC) and cannabidiol (CBD) — in a specific formulation containing 2.5 mg of THC and 30 mg of CBD. The drug is designed for sublingual administration (under the tongue), utilizing pharma-grade cannabinoid APIs sourced from BOL Pharma's own GAP-certified organic growing facilities and cGMP-certified production plant. While the specific molecular mechanism and disease indication for this particular pipeline candidate have not been publicly disclosed, the combination aims to leverage the synergistic effects of cannabinoids on the endocannabinoid system, primarily through interaction with cannabinoid receptors CB1 and CB2.

Other names

THC + CBDTHC + CBD sublingual tablet